Roberta Loddo

Roberta Loddo

Auto-generated profile, based on publicly available information

Roberta Loddo


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Michele TonelliMichele Tonelli
Michele Tonelli
FNFederica Novelli
Federica Novelli
BTBruno Tasso
Bruno Tasso
IVIana Vazzana
Iana Vazzana
ANNA SPARATOREANNA SPARATORE
ANNA SPARATORE
RLRoberta Loddo
Roberta Loddo

1 November 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IBIrene Briguglio
Irene Briguglio
RLRoberta Loddo
Roberta Loddo
ELErik Laurini
Erik Laurini
MFMaurizio Fermeglia
Maurizio Fermeglia
SPSandra Piras
Sandra Piras
ACAntonio Carta
Antonio Carta

9 April 2019 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
NDNicoletta Desideri
Nicoletta Desideri
RFRossella Fioravanti
Rossella Fioravanti
LMLuca Proietti Monaco
Luca Proietti Monaco
EAElena Maria Atzori
Elena Maria Atzori
ACAntonio Carta
Antonio Carta
RLRoberta Loddo
Roberta Loddo
A series of N-((3-phenyl-1-(phenylsulfonyl)-1H-pyrazol-4-yl)methyl)anilines 7a-p and 8a-l, structurally related to previously synthesized and tested (N-(1,3-diphenyl-1H-pyrazol-4-yl)methyl)anilines (1a-v), were designed and synthesized. The new derivatives were evaluated in cell-based assays for their cytotoxicity and antiviral activity against a large panel of RNA and DNA viruses of public health significance. Generally, the tested compounds did not display cytotoxicity toward the cell lines used. The majority of derivatives 7a-p were able to interfered with YFV and RSV replication in the micromolar range showing a marked improvement in potency and selectivity with respect to the reference inhibitors 6-azauridine and ribavirin, respectively. The introduction of a p-methoxy substituent on the phenylsulfonyl group (compounds 8a-l) completely abolished the anti-RSV activity and reduced or eliminated the potency against YFV. On the contrary, several p-methoxy analogs were able to interfere with BVDV replication with a comparable (8b, 8c, 8g, and 8k) or better (8a and 8f) potency than the reference inhibitor, ribavirin. Compound 7e, selected for time of addition experiments on BHK-21 cell cultures infected with YFV, achieved the highest reduction of virus titer when added 2 h post infection and maintained up to 4 h post infection.

1 June 2015 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RFrossella fioravanti
rossella fioravanti
NDNicoletta Desideri
Nicoletta Desideri
Mariangela BiavaMariangela Biava
Mariangela Biava
PDPaolo Droghini
Paolo Droghini
EAElena Maria Atzori
Elena Maria Atzori
RLRoberta Loddo
Roberta Loddo

1 November 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RLRoberta Loddo
Roberta Loddo
FNFederica Novelli
Federica Novelli
ANNA SPARATOREANNA SPARATORE
ANNA SPARATORE
BTBruno Tasso
Bruno Tasso
Michele TonelliMichele Tonelli
Michele Tonelli
PCPaolo La Colla
Paolo La Colla

4 May 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
RIRoberta Ibba
Roberta Ibba
SPSandra Piras
Sandra Piras
PCPaola Corona
Paola Corona
FRFederico Riu
Federico Riu
RLRoberta Loddo
Roberta Loddo
ACAntonio Carta
Antonio Carta
Cancer and viral infections continue to threaten humankind causing death worldwide. Hence, the discovery of new anticancer and antiviral agents still represents a major scientific goal. Heterocycles designed to mimic the chemical structure of natural pyrimidines and purines have been designed over the years, exerting their activity acting as false substrates on several different targets. We reported a series of bis-benzotriazole-dicarboxamide derivatives which inhibit viral helicase of poliovirus, and hence we planned structure modifications to obtain different series of new dicarboxamides. Here, the synthesis and characterization of 56 new compounds: 31 bis-benzotriazole dicarboxamides and 25 mono-substituted acidic derivatives are reported. The synthesized compounds were tested for their antiviral and antitumor activity. Mostly, compounds 4a, 4c and 4d showed antiviral activity against tested Picornaviruses, Coxsackievirus B5 and Poliovirus-1. Likewise, four derivatives (3b, 3d, 4d, 9b) showed notable antiproliferative activity inhibiting cell growth in two distinct antitumor screenings. Compound 3b was selected as the antitumor lead compound for the wide range of activity and the potency proved. The lead compound was proved to induce apoptosis in SK-MES1 tumor cells, in a dose-dependent manner.